Anatumomab mafenatox
Anatumomab mafenatox
Anatumomab mafenatox (pronunciation: an-a-tu-mo-mab ma-fe-na-tox) is a monoclonal antibody designed for the treatment of certain types of cancer. It is a biopharmaceutical product that is still in the experimental stages of development.
Etymology
The name "Anatumomab mafenatox" is derived from the following components: "Anatu" refers to the target antigen, "momab" indicates that it is a fully human monoclonal antibody, and "mafenatox" is a reference to the toxin that the antibody is designed to deliver to cancer cells.
Function
Anatumomab mafenatox works by binding to a specific antigen found on the surface of cancer cells. Once bound, the toxin component of the drug is internalized by the cell, where it can cause cell death. This targeted approach is designed to minimize damage to healthy cells, a common side effect of traditional chemotherapy.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Biopharmaceutical: A type of drug produced using biotechnology.
- Antigen: A substance that the immune system recognizes as foreign and responds to by producing antibodies.
- Chemotherapy: A type of cancer treatment that uses drugs to destroy cancer cells.
See Also
External links
- Medical encyclopedia article on Anatumomab mafenatox
- Wikipedia's article - Anatumomab mafenatox
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski